Insider Buying: Immunome, Inc. (NASDAQ:IMNM) Insider Acquires 15,805 Shares of Stock

Immunome, Inc. (NASDAQ:IMNM) insider Robert Lechleider bought 15,805 shares of Immunome stock in a transaction that occurred on Thursday, November 21st. The stock was bought at an average price of $9.48 per share, with a total value of $149,831.40. Following the purchase, the insider now owns 15,805 shares of the company’s stock, valued at $149,831.40. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Immunome Trading Up 13.5 %

NASDAQ IMNM opened at $11.15 on Tuesday. Immunome, Inc. has a 1-year low of $6.93 and a 1-year high of $30.96. The company has a 50 day moving average of $12.49 and a 200-day moving average of $13.55. The firm has a market cap of $695.98 million, a price-to-earnings ratio of -1.37 and a beta of 1.82.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on IMNM. Wedbush reissued an “outperform” rating and set a $33.00 price objective on shares of Immunome in a report on Friday, October 25th. Piper Sandler dropped their price objective on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. Finally, Stephens assumed coverage on shares of Immunome in a report on Friday, November 8th. They set an “overweight” rating and a $30.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Immunome presently has a consensus rating of “Buy” and a consensus target price of $28.83.

Hedge Funds Weigh In On Immunome

Several institutional investors have recently bought and sold shares of the business. Quest Partners LLC acquired a new stake in Immunome in the 2nd quarter valued at about $81,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Immunome in the second quarter valued at approximately $97,000. Arizona State Retirement System boosted its stake in Immunome by 9.2% in the second quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock valued at $131,000 after acquiring an additional 918 shares during the last quarter. AQR Capital Management LLC grew its holdings in Immunome by 34.6% during the 2nd quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock worth $194,000 after acquiring an additional 4,129 shares during the period. Finally, Sequoia Financial Advisors LLC bought a new stake in shares of Immunome during the 2nd quarter valued at $206,000. Institutional investors own 44.58% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.